See more : Royal Bafokeng Platinum Limited (RBP.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Acasti Pharma Inc. (ACST.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acasti Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Trinitan Metals and Minerals Tbk (PURE.JK) Income Statement Analysis – Financial Results
- Korea Electric Power Corporation (KEP) Income Statement Analysis – Financial Results
- Nature Wood Group Limited American Depositary Shares (NWGL) Income Statement Analysis – Financial Results
- Interparfums SA (ITP.PA) Income Statement Analysis – Financial Results
- Western New England Bancorp, Inc. (WNEB) Income Statement Analysis – Financial Results
Acasti Pharma Inc. (ACST.V)
About Acasti Pharma Inc.
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 14.25M | 18.45M | 19.58M | 11.94M | 7.63M | 0.00 |
| Cost of Revenue | 67.22M | 80.94M | 53.13M | 46.31M | 21.97M | 9.77M |
| Gross Profit | -52.97M | -62.50M | -33.55M | -34.37M | -14.34M | -9.77M |
| Gross Profit Ratio | -371.72% | -338.76% | -171.31% | -287.81% | -187.91% | 0.00% |
| Research & Development | 68.65M | 82.85M | 54.79M | 46.31M | 21.97M | 9.77M |
| General & Administrative | 18.54M | 17.07M | 17.71M | 16.72M | 6.84M | 4.39M |
| Selling & Marketing | 1.65M | 2.11M | 2.03M | 0.00 | 0.00 | 0.00 |
| SG&A | 20.19M | 19.18M | 19.74M | 16.72M | 6.84M | 4.39M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.67M | 12.30M | 10.15M | 9.38M | 1.10M | 2.34M |
| Cost & Expenses | 79.88M | 93.24M | 63.28M | 55.69M | 23.06M | 12.11M |
| Interest Income | 946.00K | 871.00K | 386.00K | 710.00K | 778.00K | 606.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.60M | 4.64M | 4.15M | 3.07M | 640.00K | 398.00K |
| EBITDA | -69.55M | -77.03M | -49.14M | -48.02M | -20.54M | -13.76M |
| EBITDA Ratio | -488.13% | -417.57% | -250.89% | -402.09% | -269.24% | 0.00% |
| Operating Income | -73.16M | -81.67M | -53.29M | -51.09M | -21.18M | -14.16M |
| Operating Income Ratio | -513.40% | -442.73% | -272.08% | -427.78% | -277.62% | 0.00% |
| Total Other Income/Expenses | 8.47M | 6.01M | 9.20M | 8.05M | 4.97M | 1.44M |
| Income Before Tax | -64.69M | -75.66M | -44.08M | -43.04M | -16.21M | -12.72M |
| Income Before Tax Ratio | -453.96% | -410.15% | -225.09% | -360.38% | -212.52% | 0.00% |
| Income Tax Expense | 230.00K | 1.00K | 0.00 | 0.00 | 24.00K | 4.00K |
| Net Income | -64.92M | -75.67M | -44.08M | -43.04M | -16.24M | -12.72M |
| Net Income Ratio | -455.58% | -410.15% | -225.09% | -360.38% | -212.83% | 0.00% |
| EPS | -0.99 | -2.30 | -1.69 | -2.41 | -17.76 | -13.95 |
| EPS Diluted | -0.99 | -2.30 | -1.69 | -2.41 | -17.76 | -13.95 |
| Weighted Avg Shares Out | 65.51M | 32.83M | 26.04M | 17.86M | 914.37K | 911.78K |
| Weighted Avg Shares Out (Dil) | 65.51M | 32.83M | 26.04M | 17.86M | 914.38K | 911.78K |
Source: https://incomestatements.info
Category: Stock Reports